Halozyme Q3 net income rises 41% to $247.05 million

PUBT · 19h ago
Halozyme Q3 net income rises 41% to $247.05 million
  • Halozyme Therapeutics’ third-quarter 2026 GAAP diluted earnings rose 41% year-over-year to $2.01 per share.
  • Total revenue climbed 39% to $492.97 million, while royalty revenue increased 44% to $341 million year-over-year.
  • A Dutch patent court granted an injunction blocking Merck’s Keytruda Qlex launch in eight European markets for infringing a Halozyme patent.
  • Full-year 2026 total revenue guidance increased to $1.86 billion–$1.93 billion, representing 33%–38% growth over 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202611051605PR_NEWS_USPR_____LA90634) on November 05, 2026, and is solely responsible for the information contained therein.